Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation StudySerena Yun‐Chen Tsai, Kevin Sheng‐Kai, Harland S. Winter et al.|Pediatric Drugs|2025Cited by 2
Comparative risk of serious infection among biologic therapies for inflammatory bowel disease in pediatric patients: A target trial emulationSerena Yun‐Chen Tsai, Kevin Sheng‐Kai, Ashwin N. Ananthakrishnan et al.|Journal of Pediatric Gastroenterology and Nutrition|2025Cited by 1